Nov. 13 at 1:48 AM
$SNDX Revuforj product sales by quarter post launch versus 3 peer therapies acquired for
$1.7 to
$1.9B attached. Revuforj was only approved for its KMT2A label during these 4 quarters. Revuforj's mNPM1 label came in Revuforj's 5th quarter on the market. Raw sales data to the lower right.
Revuforj, when only approved for KMT2A leukemias, comfortably outsold all 3 products. We post considerable SNDX analysis here on STs but this one could be especially meaningful
If new drugs are worth some multiple of actual sales, and Revuforj is outselling these 3 drugs by factors of 1.2 to 1.8X then, by itself, these data points suggest Revuforj in only its KMT2A label is worth north of
$2B. This is not investment advice as obviously there are multiple other data points to consider but actual sales are meaningful.
Imagine the value Revuforj's mNPM1 label could bring to SNDX's valuation profile. Obviously, Niktimvo (50/50 with
$INCY ) is also not considered.
Pushback?
$AVDL ?
$XBI $IBB
